| Identification | Back Directory | [Name]
Dacarbazine citrate | [CAS]
64038-56-8 | [Synonyms]
DTIC citrate
Dacarbazine citrate | [Molecular Formula]
C12H18N6O8 | [MDL Number]
MFCD01721729 | [MOL File]
64038-56-8.mol | [Molecular Weight]
374.31 |
| Hazard Information | Back Directory | [Uses]
Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC50 values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma[1][2]. | [in vivo]
Dacarbazine citrate (1 mg/kg, i.p.) evokes a concentration-dependent calcium response and the maximum calcium response with an EC50 value of 16 μM in a subset of cells of cultured mouse DRG neurons and excites TRPA1 in rodent sensory neurons[3].
Dacarbazine citrate (1 mg/kg, i.p.; 1, 3, 5 and 7 days for chronic pain or 1 mg/kg, i.p. for acute treatment) induces mechanical and cold allodynia in mice[3].
Dacarbazine citrate-induced nociception can be reduced by TRPA1-deficient mice and antisense oligonucleotide for the TRPA1 receptor[3].
Dacarbazine citrate-induced chronic nociception can be reduced by selective TRPA1 receptor antagonists and antioxidants[3].
Dacarbazine citrate-induced nociception can be resisted by RPA1 antagonist or an antioxidant in a tumor-associated cancer pain model[3]. | Animal Model: | C57BL/6, Trpa1+/+ or Trpa1?/? mice[3] | | Dosage: | 1 mg/kg | | Administration: | 1 mg/kg, i.p. (for acute treatment);
1 mg/kg, i.p.; 1, 3, 5 and 7 days (for chronic pain)
| | Result: | Caused mechanical allodynia with acute or repeated administration. |
| [References]
[1] Abdullah A Al-Badr, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol DOI:10.1016/bs.podrm.2015.12.002
[2] J M Rojo, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51. DOI:10.1159/000238218
[3] Int J Cancer, et al. Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activation in mice. Int J Cancer. 2020 May 15;146(10):2797-2809. DOI:10.1002/ijc.32648 |
|
|